What question did this study set out to answer?

To evaluate the association between minimal residual disease negativity rates and progression-free survival in follicular lymphoma.

December 8, 2025BloodOpen Access

Trial-level meta-analysis of minimal residual disease and progression-free survival in follicular lymphoma

View Full Paper

Ask AI

Bookmark

Authors

HHHelen HeUniversity of East Anglia

Discussion

Member takes

Implication

Meta-analysis reveals moderate correlation between MRD negativity and progression-free survival in follicular lymphoma, suggesting MRD as a biomarker.

Key Points

To evaluate the association between minimal residual disease negativity rates and progression-free survival in follicular lymphoma.
Conducted a trial-level meta-analysis of randomized controlled trials and single-arm studies from 2000 to 2022
Assessed MRD status via next generation sequencing and polymerase chain reaction
Evaluated trial-level associations using Pearson and Spearman correlation coefficients
Identified 7 trials with 3799 patients contributing 12 cohorts
Observed a moderate correlation between MRD negativity rates and median progression-free survival
Weighted Pearson regression showed R2 of 0.67, indicating 70% variability in median PFS explained by MRD negativity

Cite This Study

Helen He (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d1fa https://doi.org/10.1182/blood-2025-7104

View Full Paper

Ask AI

Bookmark

Implication

Meta-analysis reveals moderate correlation between MRD negativity and progression-free survival in follicular lymphoma, suggesting MRD as a biomarker.

Trial-level meta-analysis of minimal residual disease and progression-free survival in follicular lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Trial-level meta-analysis of minimal residual disease and progression-free survival in follicular lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider